Our data suggest that FGF23 itself may not be a primary target for reducing vascular damage in CKD but rather support the concept that FGF23 portrays vascular pathology associated with a disordered mineral metabolism such as hyperphosphatemia, low levels of vitamin D and secondary hyperparathyroidism. This evidence concerns the gene FGF23 and hyperphosphatemia.